SK283118B6 - Stereoizomérne formy itrakonazolu a saperkonazolu, spôsob ich výroby, ich komplexy, spôsob výroby týchto komplexov, farmaceutický prípravok a ich použitie - Google Patents

Stereoizomérne formy itrakonazolu a saperkonazolu, spôsob ich výroby, ich komplexy, spôsob výroby týchto komplexov, farmaceutický prípravok a ich použitie Download PDF

Info

Publication number
SK283118B6
SK283118B6 SK1106-94A SK110694A SK283118B6 SK 283118 B6 SK283118 B6 SK 283118B6 SK 110694 A SK110694 A SK 110694A SK 283118 B6 SK283118 B6 SK 283118B6
Authority
SK
Slovakia
Prior art keywords
triazol
phenyl
cyclodextrin
piperazinyl
methylpropyl
Prior art date
Application number
SK1106-94A
Other languages
English (en)
Slovak (sk)
Other versions
SK110694A3 (en
Inventor
Jan Heeres
Jean Louis Mesens
Jozef Peeters
Original Assignee
Janssen Pharmaceutica N. V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25316567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK283118(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N. V. filed Critical Janssen Pharmaceutica N. V.
Publication of SK110694A3 publication Critical patent/SK110694A3/sk
Publication of SK283118B6 publication Critical patent/SK283118B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
SK1106-94A 1992-03-18 1993-03-10 Stereoizomérne formy itrakonazolu a saperkonazolu, spôsob ich výroby, ich komplexy, spôsob výroby týchto komplexov, farmaceutický prípravok a ich použitie SK283118B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85364892A 1992-03-18 1992-03-18
PCT/EP1993/000552 WO1993019061A1 (en) 1992-03-18 1993-03-10 Itraconazole and saperconazole stereoisomers

Publications (2)

Publication Number Publication Date
SK110694A3 SK110694A3 (en) 1995-04-12
SK283118B6 true SK283118B6 (sk) 2003-02-04

Family

ID=25316567

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1106-94A SK283118B6 (sk) 1992-03-18 1993-03-10 Stereoizomérne formy itrakonazolu a saperkonazolu, spôsob ich výroby, ich komplexy, spôsob výroby týchto komplexov, farmaceutický prípravok a ich použitie

Country Status (22)

Country Link
US (1) US5998413A (de)
EP (1) EP0631578B1 (de)
KR (1) KR100243534B1 (de)
AT (1) ATE201408T1 (de)
AU (1) AU665988B2 (de)
CA (1) CA2117651C (de)
CZ (1) CZ286619B6 (de)
DE (1) DE69330248T2 (de)
DK (1) DK0631578T3 (de)
ES (1) ES2158859T3 (de)
FI (1) FI113175B (de)
GR (1) GR3036368T3 (de)
HK (1) HK1010729A1 (de)
HU (1) HU221189B1 (de)
NO (1) NO307786B1 (de)
NZ (1) NZ249494A (de)
PL (1) PL172358B1 (de)
PT (1) PT631578E (de)
RU (1) RU2127733C1 (de)
SK (1) SK283118B6 (de)
WO (1) WO1993019061A1 (de)
ZA (1) ZA931906B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6096094A (en) * 1993-01-27 1994-08-15 Georgetown University Method and composition employing (2r,4s) itraconazole
TW349870B (en) * 1993-09-30 1999-01-11 Janssen Pharmaceutica Nv An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
US5486625A (en) * 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
ES2112151B1 (es) * 1995-03-17 1999-09-16 Menarini Lab Nuevos compuestos homoquirales para la preparacion de ketoconazol, terconazol y antifungicos relacionados, procedimiento para su fabricacion y utilizacion de los mismos.
DE69733664T3 (de) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
CN1165291C (zh) * 1996-05-20 2004-09-08 詹森药业有限公司 具有改进的生物利用度的抗真菌组合物
WO1998021203A1 (en) * 1996-11-12 1998-05-22 Sepracor, Inc. 2r,4s,s,r- and 2s,4r,s,r-hydroxyitraconazole
JP2001504121A (ja) * 1996-11-12 2001-03-27 セプラコール，インク． ２ｒ，４ｓ，ｒ，ｓ―および２ｓ，４ｒ，ｒ，ｓ―ヒドロキシイトラコナゾール―およびヒドロキシサパーコナゾール誘導体
EP0938484A1 (de) * 1996-11-12 1999-09-01 Sepracor, Inc. 2r,4s,r,r- und 2s,4r,r,r-hydroxyitraconazol
CA2269608A1 (en) 1996-11-12 1998-05-22 Sepracor Inc. 2r,4s,s,s- and 2s,4r,s,s-hydroxyitraconazole
CN1244125A (zh) * 1996-11-12 2000-02-09 塞普拉科有限公司 使用顺式－羟基依他康唑以避免依他康唑和羟基依他康唑的副作用
DE69824834T2 (de) 1997-02-11 2005-07-21 Janssen Pharmaceutica N.V. Azole enthaltende antifungale aminosäure-ester
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
EP0957101A1 (de) * 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Wasserlösliche Azole als Breitspektrum-antifungus
US6497905B1 (en) 1999-03-24 2002-12-24 R.P. Scherer Technologies, Inc. Aqueous solubility pharmaceutical formulations
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7446107B2 (en) * 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1511490A4 (de) * 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc Neue kristalline conazol-formen und verwandte prozesse, pharmazeutische zusammensetzungen und verfahren
EP1515703A1 (de) 2002-06-21 2005-03-23 Transform Pharmaceuticals, Inc. Pharmazeutische zusammensetzungen mit verbesserter auflösung
KR100446256B1 (ko) * 2002-07-11 2004-09-01 경동제약 주식회사 고 광학선택성을 가지는시스-2-(브로모메틸)-2-(2,4-디클로로페닐)-13-디옥소란-4-메틸알콜의 제조방법
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20090028938A1 (en) 2005-08-08 2009-01-29 Abbott Gmbh & Co. Kg Dosage forms with improved bioavailability
EP1912625B1 (de) 2005-08-08 2016-04-13 AbbVie Deutschland GmbH & Co KG Itraconazol-zusammensetzungen mit verbesserter bioverfügbarkeit
AU2006283040B2 (en) 2005-08-22 2011-08-25 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
US9072660B2 (en) 2011-09-09 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Topical itraconazole formulations and uses thereof
CN102379844A (zh) * 2011-10-31 2012-03-21 广州维美投资有限公司 一种伊曲康唑异构体注射剂
CN105061411A (zh) * 2015-06-23 2015-11-18 扬州艾迪生物科技有限公司 一种光学异构体2s,4r,2’s-伊曲康唑晶型及制备方法与应用
CN106146480B (zh) * 2016-07-18 2019-08-06 山东罗欣药业集团恒欣药业有限公司 一种伊曲康唑的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4490530A (en) * 1981-01-14 1984-12-25 Janssen Pharmaceutica N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)-methyl-1H-imidazoles and 1H-1,2,4-triazoles
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
FR2622198B1 (fr) * 1987-10-21 1992-04-30 Mero Rousselot Satia Compositions granulees de polysaccharides a dissolution aqueuse instantanee, procede pour leur preparation et utilisation
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
US5214046A (en) * 1989-07-27 1993-05-25 Hoffmann-La Roche Inc. Substituted aminoalkoxybenzene anti-fungicidal compositions and use
AU6096094A (en) * 1993-01-27 1994-08-15 Georgetown University Method and composition employing (2r,4s) itraconazole

Also Published As

Publication number Publication date
NO943450L (no) 1994-11-11
US5998413A (en) 1999-12-07
NZ249494A (en) 1996-04-26
FI944311A (fi) 1994-09-16
GR3036368T3 (en) 2001-11-30
HK1010729A1 (en) 1999-06-25
CZ286619B6 (cs) 2000-05-17
KR100243534B1 (ko) 2000-03-02
HU221189B1 (en) 2002-08-28
AU3632493A (en) 1993-10-21
ES2158859T3 (es) 2001-09-16
CA2117651C (en) 2006-01-03
NO943450D0 (no) 1994-09-16
EP0631578A1 (de) 1995-01-04
PT631578E (pt) 2001-11-30
DE69330248D1 (de) 2001-06-28
WO1993019061A1 (en) 1993-09-30
NO307786B1 (no) 2000-05-29
RU94045798A (ru) 1996-07-20
HUT71835A (en) 1996-02-28
RU2127733C1 (ru) 1999-03-20
CA2117651A1 (en) 1993-09-30
DK0631578T3 (da) 2001-08-27
CZ221594A3 (en) 1995-01-18
ZA931906B (en) 1994-09-17
SK110694A3 (en) 1995-04-12
HU9402656D0 (en) 1994-11-28
PL172358B1 (en) 1997-09-30
FI944311A0 (fi) 1994-09-16
ATE201408T1 (de) 2001-06-15
KR950700904A (ko) 1995-02-20
EP0631578B1 (de) 2001-05-23
DE69330248T2 (de) 2002-03-21
AU665988B2 (en) 1996-01-25
FI113175B (fi) 2004-03-15

Similar Documents

Publication Publication Date Title
SK283118B6 (sk) Stereoizomérne formy itrakonazolu a saperkonazolu, spôsob ich výroby, ich komplexy, spôsob výroby týchto komplexov, farmaceutický prípravok a ich použitie
PL181947B1 (en) Water-soluble azole-type antimycotic agents
HU204819B (en) Process for producing pharmaceutical compositions comprising 1h-imidazoles and 1h-1,2,4-triazoles as active ingredient and for producing the active ingredients
US6448244B1 (en) Water soluble azoles as broad-spectrum antifungals
US6346518B1 (en) Itraconazole and saperconazole stereoisomers
AP1379A (en) 2,4,4-Trisubstituted-1,3-dioxolane antifungals.
US6583136B1 (en) Antifungal ethers
US5236944A (en) Compounds, compositions and anti-neoplastic methods
MXPA00011155A (es) Azoles solubles en agua como antifungicos de amplio espectro